Navigation Links
Delcath Reports Second Quarter 2012 Financial Results And Highlights Recent Accomplishments

NEW YORK, Aug. 7, 2012 /PRNewswire/ -- Delcath Systems (NASDAQ: DCTH) today announced financial results and highlights for its second quarter 2012 ended June 30, 2012 and recent corporate accomplishments. 

Highlights for the second quarter 2012 and recent weeks include:

  • Recognition of first product revenue in Delcath history
  • FDA acceptance of the IND Amendments for use of the Generation 2 filter in the U.S. Expanded Access Program, compassionate use, and future clinical trials
  • New drug application (NDA) filing with the FDA for the Company's proprietary chemosaturation system on target for mid-August 2012
  • Addition of five leading cancer centers in the EU to the CHEMOSAT® initial launch and training program; a total 13 CHEMOSAT centers have been signed with presence in all seven key target EU markets
  • Deployment of Quintiles trained medical science liaisons field force in the key target markets in Europe
  • To date 16 CHEMOSAT procedures performed at five EU centers; 13 patients with liver dominant metastases from multiple tumor types have been treated, including cutaneous melanoma, ocular melanoma, gastric cancer, breast cancer and cholangiocarcinoma
  • Raised $21.1 million in net proceeds through a follow on offering to fund operational progress and CHEMOSAT European launch
  • Board of Directors strengthened with the addition of pharmaceutical industry veterans Laura A. Brege and Tasos G. Konidaris.
  • "During the second quarter, we made important progress with the European launch of CHEMOSAT, and generated our first product revenue in the Company's history," said Eamonn P. Hobbs, President and CEO of Delcath.  "We have now signed agreements with 13 leading European Union cancer centers, exceeding our original expectations, and intend to sign additional centers in the coming months. Our medical science liaisons are in the field in our seven target markets educating oncologists on the potential of the CHEMOSAT treatment for their patients with liver dominant disease.  To date, patients afflicted with liver metastases from five different types of cancer have been treated with CHEMOSAT. During the remainder of the year, our commercial focus in Europe will be to continue to bring clinical centers on line while we work with referring physicians to expand clinical adoption of the CHEMOSAT system as an important therapeutic option for these patients.

    "In the U.S., our New Drug Application (NDA) is on schedule and we expect to submit the file to the FDA by mid-August," continued Mr. Hobbs.  "Our amendments to our Investigational New Drug (IND) application to include Generation 2 in our Expanded Access Program and all future clinical trials and compassionate use cases were accepted by the FDA. Additionally, after consultation with the FDA, we have agreed to include the addition of Generation 2 in our NDA submission as a technical change to the Chemistry, Manufacturing, and Control module."

    For the three months ended June 30, 2012, Delcath's operating loss was $15.4 million, which included approximately $1.0 million in non-cash stock-based compensation expense.  Operating loss for the three months ended June 30, 2011 was $10.5 million, which included approximately $1.2 million in non-cash stock-based compensation expense.  Selling, general and administrative (SG&A) expenses were $7.2 million for the second quarter of 2012, compared to $5.2 million for the same period in 2011.  The increase was primarily due to an increase in sales, marketing and operational support staff in the EU. Research and development (R&D) expenses were $8.2 million for the second quarter of 2012, compared to $5.2 million for the same period in 2011.  The increase was primarily due to global regulatory efforts including continued preparation of the NDA submission to the FDA and the training and deployment of third party medical science liaisons.

    At June 30, 2012, cash, cash equivalents and certificates of deposit were $29.3 million, compared to $30.8 million at December 31, 2011.  Gross cash spend in the second quarter 2012 was $14.2 million, as compared to $8.2 million in the same period in the prior year. The increase was primarily driven by NDA submission related costs and staff increases in various functions to support EU commercialization. Average monthly operating gross spend was $4.7 million in the second quarter, a decrease from $4.9 million in the first quarter of 2012.  Following the anticipated NDA submission, Delcath expects average monthly cash spend to decrease to between $3 million to $4 million for the fourth quarter of 2012.

    Conference Call and Webcast The Company will host a conference call today, August 7, 2012 at 8:30 a.m. ET.  To participate in the live call by telephone, please dial 800-762-8779 for domestic participants and 480-629-9645 for international participants. To access the live webcast, go to the Events & Presentations page on Delcath's website at

    A taped replay of the conference call will also be available beginning approximately two hours after the call's conclusion and will be available for seven days. This replay can be accessed by dialing 800-406-7325 for domestic callers and 303-590-3030 for international callers, both using passcode 4548817.
    An archived webcast will also be available at

    About Delcath SystemsDelcath Systems, Inc. is a specialty pharmaceutical and medical device company focused on oncology. Delcath's proprietary system for chemosaturation is designed to administer high dose chemotherapy and other therapeutic agents to diseased organs or regions of the body, while controlling the systemic exposure of those agents. The Company's initial focus is on the treatment of primary and metastatic liver cancers. In 2010, Delcath announced that its randomized Phase III clinical trial for patients with metastatic melanoma in the liver had successfully achieved the study's primary endpoint of extended hepatic progression-free survival. The Company also completed a multi-arm Phase II trial to treat other liver cancers. The Company obtained authorization to affix a CE Mark for the Delcath Hepatic CHEMOSAT® delivery system in April 2011 and for the second generation hemofiltration cartridge for CHEMOSAT in April 2012. The right to affix the CE mark allows the Company to market and sell the CHEMOSAT system in Europe. The Company has not yet received FDA approval for commercial sale of its system in the United States. The Company continues with the preparation of its NDA submission and intends to seek FDA approval for commercial sale of its chemosaturation system with melphalan. For more information, please visit the Company's website at

    Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This news release contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to: the benefits of the Generation 2 CHEMOSAT system and market acceptance of the same, patient outcomes using the Generation 2 system, the timing of the supply and distribution of the CHEMOSAT system to early launch centers in Europe, the time required to build inventory and establish commercial operations in Europe, adoption, use and resulting sales, if any, for the Hepatic CHEMOSAT delivery system in the EEA, our ability to successfully commercialize the chemosaturation system and the potential of the chemosaturation system as a treatment for patients with terminal metastatic disease in the liver, acceptability of the Phase III clinical trial data by the FDA, our ability to address the issues raised in the Refusal to File letter received from the FDA and the timing of our re-submission of our NDA, re-submission and acceptance of the Company's NDA by the FDA, approval of the Company's NDA for the treatment of metastatic melanoma to the liver, adoption, use and resulting sales, if any, for the chemosaturation system in the United States, approval of the current or future chemosaturation system for other indications, actions by the FDA or other foreign regulatory agencies, our ability to obtain reimbursement for the CHEMOSAT system, our ability to successfully enter into distribution and strategic partnership agreements in foreign markets and the corresponding revenue associated with such foreign markets, uncertainties relating to the results of research and development projects and future clinical trials, the timing and use, if any, of the line of credit from SVB, and our ability to access this facility, and uncertainties regarding our ability to obtain financial and other resources for any research, development and commercialization activities. These factors, and others, are discussed from time to time in our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances after the date they are made.Contact Information:  Investor Contact:Media Contact:Doug Sherk/Gregory GinJanine McCargoEVC GroupEVC Group415-568-4887/646-445-48646-688-0425 DELCATH SYSTEMS, INC.Condensed Consolidated Statements of Operations and Comprehensive Lossfor the Three and Six Months Ended June 30, 2012 and 2011(in thousands, except share and per share data)Three months ended June 30,Six months ended June 30,2012201120122011Revenue





    -Cost of sales----Gross profit106-106-Operating expenses:Selling, general and






    9,404Research and development18,2045,24815,3358,896Total operating expenses15,42210,48629,97818,300Operating loss(15,316)(10,486)(29,872)(18,300)Change in fair value of the warrant liability, net9175,02757910,992Interest income4-71Other expense and interest expense(117)-(115)-Net loss





    (7,307)Common share data:Basic and diluted loss per share





    (0.17)Weighted average number of basic and diluted common shares outstanding54,847,80742,988,24051,582,45842,971,148Comprehensive Loss





    (9,000)Note 1:Includes non-cash stock-based compensation expense as follows:Three months ended June 30, Six months ended June 30, 2012201120122011Selling, general and administrative





    1,660Research and development352396722801Total stock-based compensation expense





    2,461DELCATH SYSTEMS, INC.Condensed Consolidated Balance Sheetsas of June 30, 2012 and December 31, 2011(in thousands, except share data)June 30, December 31, 20122011Assets:Current assetsCash and cash equivalents$


    25,777Investments – Certificates of deposit-4,980Inventories516-Accounts receivables102-Prepaid expenses and other current assets1,4251,231Total current assets31,32931,988Property, plant and equipmentLand154154Furniture and fixtures936880Machinery and equipment1,4541,371Computer software and equipment1,8991,212Leasehold improvements1,5741,1486,0174,765Less: accumulated depreciation(2,211)(1,512)Property, plant and equipment, net3,8063,253Total assets$


    35,241Liabilities and Stockholders' Equity:Current liabilitiesAccounts payable and accrued expenses$


    6,398Warrant liability5,9152,439Total current liabilities13,3278,837Deferred revenue300300Commitments and contingencies--Stockholders' equityPreferred stock, $.01 par value; 10,000,000 shares authorized; no shares issued and outstanding at June 30, 2012 and December 31, 2011--Common stock, $.01 par value; 170,000,000 shares authorized; 65,744,017 and 48,237,630 shares issued and 65,715,917 and 48,209,534 shares outstanding at June 30, 2012 and December 31, 2011, respectively657482Additional paid-in capital197,243172,613Retained earnings(176,341)(146,940)Treasury stock, at cost; 28,100 shares at June 30, 2012 and December 31, 2011(51)(51)Total stockholders' equity21,50826,104Total liabilities and stockholders' equity$




    SOURCE Delcath Systems, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Delcath Systems, Inc. Secures $20 Million Credit Facility
    2. Delcath Highlights First Quarter 2012 And Recent Accomplishments
    3. Delcath to Webcast Managements Presentation at Annual Meeting of Stockholders
    4. Delcath Prices $20 Million Public Offering of Common Stock and Warrants
    5. Delcath To Offer Second Generation Hemofiltration Cartridge In U.S. Expanded Access Program
    6. Delcath Announced Changes To Board Of Directors
    7. Delcath To Present At JMP Securities Healthcare Conference On July 12
    8. Delcath To Conduct Second Quarter 2012 Results Conference Call
    9. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
    10. Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed.
    11. Kelyniam Global Inc. Reports Record Cranial Implant Revenues in the 1st Quarter of 2012
    Post Your Comments:
    (Date:10/12/2017)... AVACEN Medical , Inc. (AVACEN) announced that Frost & ... Innovation Award for Its fibromyalgia pain management device. The ... market research by Frost & Sullivan,s industry experts. ... product, the AVACEN 100, offers a safe and effective solution ... ...
    (Date:10/12/2017)... , Oct. 12, 2017 West Pharmaceutical ... innovative solutions for injectable drug administration, today announced that ... market opens on Thursday, October 26, 2017, and will ... and business expectations at 9:00 a.m. Eastern Time. To ... 253-336-8738 (International). The conference ID is 94093362. ...
    (Date:10/11/2017)... , Oct. 11, 2017  Caris Life Sciences ® ... fulfilling the promise of precision medicine, today announced that ... Caris, Precision Oncology Alliance™ (POA) as its 17 th ... the St. Jude Crosson Cancer Institute will help develop ... use of tumor profiling, making cancer treatment more precise ...
    Breaking Medicine Technology:
    (Date:10/13/2017)... ... October 13, 2017 , ... While it’s often important ... problem. Fortunately, an inventor from Austin, Texas, has identified a solution. , She developed ... darkness or restricted lighting. As such, it eliminates the need to turn on a ...
    (Date:10/13/2017)... ... , ... PurhealthRX , a leading Health and Nutrition Company, is announcing ... full spectrum CBD oil will revolutionize the rapidly growing CBD market by reducing the ... incorporated into liquid products, while reducing costs to end users. , The team of ...
    (Date:10/13/2017)... ... October 13, 2017 , ... Apple Rehab Shelton Lakes , which ... evacuation of the facility as part of a disaster drill on October 3rd. , ... and Shelton City Emergency Manager, as well as the Connecticut Long Term Care ...
    (Date:10/13/2017)... ... October 13, 2017 , ... Ellevate Network, the leading network for professional women, ... towards gender equality at their inaugural Summit in New York City in June. The ... social audience of over 3 million. To watch the Mobilize Women video, click ...
    (Date:10/13/2017)... ... October 13, 2017 , ... Talented ... the lowdown on sciatica in a new episode of "Success Files," which is ... events and innovation and investigates each subject in-depth with passion and integrity. , ...
    Breaking Medicine News(10 mins):